Aerie Pharmaceuticals (AERI) Upgraded to “Buy” at BidaskClub
BidaskClub upgraded shares of Aerie Pharmaceuticals (NASDAQ:AERI) from a hold rating to a buy rating in a report published on Tuesday morning.
Several other research firms also recently commented on AERI. Canaccord Genuity set a $65.00 price objective on Aerie Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, August 8th. Needham & Company LLC reiterated a buy rating and issued a $76.00 price objective (up from $65.00) on shares of Aerie Pharmaceuticals in a report on Monday, October 16th. Mizuho reiterated a buy rating and issued a $87.00 price objective on shares of Aerie Pharmaceuticals in a report on Thursday, November 9th. Cantor Fitzgerald set a $69.00 price objective on Aerie Pharmaceuticals and gave the stock a buy rating in a report on Thursday, November 16th. Finally, Zacks Investment Research upgraded Aerie Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, October 24th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have issued a buy rating to the stock. Aerie Pharmaceuticals presently has a consensus rating of Buy and an average price target of $71.43.
Aerie Pharmaceuticals (NASDAQ AERI) opened at $60.05 on Tuesday. Aerie Pharmaceuticals has a twelve month low of $35.50 and a twelve month high of $66.60. The company has a debt-to-equity ratio of 0.78, a quick ratio of 15.24 and a current ratio of 15.24.
A number of large investors have recently made changes to their positions in AERI. Teachers Advisors LLC boosted its position in Aerie Pharmaceuticals by 5.1% in the first quarter. Teachers Advisors LLC now owns 49,726 shares of the company’s stock worth $2,255,000 after purchasing an additional 2,402 shares during the last quarter. California Public Employees Retirement System purchased a new position in Aerie Pharmaceuticals in the first quarter worth about $231,000. Aperio Group LLC boosted its position in Aerie Pharmaceuticals by 4.7% in the second quarter. Aperio Group LLC now owns 4,914 shares of the company’s stock worth $258,000 after purchasing an additional 219 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Aerie Pharmaceuticals by 813.5% in the second quarter. Russell Investments Group Ltd. now owns 232,610 shares of the company’s stock worth $12,223,000 after purchasing an additional 207,146 shares during the last quarter. Finally, Sei Investments Co. boosted its position in Aerie Pharmaceuticals by 53,632.1% in the second quarter. Sei Investments Co. now owns 15,045 shares of the company’s stock worth $790,000 after purchasing an additional 15,017 shares during the last quarter.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.